Investor Overview

Corporate Profile

Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral virus, which we refer to as LVV, adeno-associated virus, which we refer to as AAV, gene therapy platforms.

Stock Information

NASDAQ | RCKT (Common Stock)


 1.84 (11.04%)

Market Cap$834,617,085

March 19, 2019  4:00 p.m. ET

Minimum 15 minute delay, Data provided by Nasdaq

Stock chart for: RCKT.O.  Currently trading at $18.50 with a 52 week high of $25.96 and a 52 week low of $10.75.